| American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer GH Lyman, M Carrier, C Ay, M Di Nisio, LK Hicks, AA Khorana, AD Leavitt, ... Blood advances 5 (4), 927-974, 2021 | 597 | 2021 |
| Diagnosis and treatment of cancer‐related anemia JA Gilreath, DD Stenehjem, GM Rodgers American journal of hematology 89 (2), 203-212, 2014 | 254 | 2014 |
| PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer DD Stenehjem, D Tran, MA Nkrumah, S Gupta OncoTargets and therapy, 5973-5989, 2018 | 139 | 2018 |
| Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer D Waterhouse, J Lam, KA Betts, L Yin, S Gao, Y Yuan, J Hartman, S Rao, ... Lung Cancer 156, 41-49, 2021 | 91 | 2021 |
| Tumor mutational burden in lung cancer: a systematic literature review C Willis, M Fiander, D Tran, B Korytowsky, JM Thomas, F Calderon, ... Oncotarget 10 (61), 6604, 2019 | 80 | 2019 |
| Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy JI Griffiths, P Wallet, LT Pflieger, D Stenehjem, X Liu, PA Cosgrove, ... Proceedings of the National Academy of Sciences 117 (27), 16072-16082, 2020 | 64 | 2020 |
| Novel and emerging strategies in drug delivery for overcoming the blood–brain barrier DD Stenehjem, AMS Hartz, B Bauer, GW Anderson Future medicinal chemistry 1 (9), 1623-1641, 2009 | 61 | 2009 |
| Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs DE Westholm, DD Stenehjem, JN Rumbley, LR Drewes, GW Anderson Endocrinology 150 (2), 1025-1032, 2009 | 52 | 2009 |
| Panobinostat for the treatment of multiple myeloma: the evidence to date H Bailey, DD Stenehjem, S Sharma Journal of Blood Medicine, 269-276, 2015 | 47 | 2015 |
| Targeting Bacteroides in stool microbiome and response to treatment with first-line VEGF tyrosine kinase inhibitors in metastatic renal-cell carcinoma AW Hahn, C Froerer, S VanAlstine, N Rathi, EB Bailey, DD Stenehjem, ... Clinical genitourinary cancer 16 (5), 365-368, 2018 | 40 | 2018 |
| The pharmacoeconomics of breakthrough cancer pain KL Kuo, S Saokaew, DD Stenehjem Journal of pain & palliative care pharmacotherapy 27 (2), 167-175, 2013 | 35 | 2013 |
| Impact of a genetic counseling requirement prior to genetic testing DD Stenehjem, T Au, AM Sainski, H Bauer, K Brown, J Lancaster, ... BMC health services research 18, 1-11, 2018 | 33 | 2018 |
| Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma JA Kuzman, DD Stenehjem, J Merriman, AM Agarwal, SB Patel, AW Hahn, ... BMC urology 17, 1-5, 2017 | 33 | 2017 |
| Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine … EB Bailey, SK Tantravahi, A Poole, AM Agarwal, AM Straubhar, JA Batten, ... Clinical Genitourinary Cancer 13 (3), e131-e137, 2015 | 28 | 2015 |
| Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer DD Stenehjem, M Yoo, SK Unni, M Singhal, H Bauer, K Saverno, C Quah, ... Breast Cancer: Targets and Therapy, 169-177, 2014 | 28 | 2014 |
| Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies TH Au, K Wang, D Stenehjem, I Garrido-Laguna Journal of Gastrointestinal Oncology 8 (3), 387, 2017 | 26 | 2017 |
| Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis U Rochau, M Kluibenschaedl, D Stenehjem, K Kuan-Ling, J Radich, ... Leukemia research and treatment 2015, 2015 | 26 | 2015 |
| Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia U Rochau, G Sroczynski, D Wolf, S Schmidt, B Jahn, M Kluibenschaedl, ... Leukemia & lymphoma 56 (8), 2315-2325, 2015 | 24 | 2015 |
| Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs T Luczak, SJ Brown, D Armbruster, M Hundertmark, J Brown, ... Pharmacogenomics 22 (6), 345-364, 2021 | 23 | 2021 |
| Comparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients: a systematic review and network meta-analysis P Wilairat, K Kengkla, T Kaewpanan, J Kaewthong, S Ruankon, ... European Journal of Hospital Pharmacy 27 (2), 103-110, 2020 | 22 | 2020 |
